Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Tetra Bio-Pharma And Cannvalate Enter Into Partnership

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contemplating a private placement of common shares in the capital of the company with Cannvalate for aggregate proceeds to the company of up to CA$7.5 million ($5.86 million).

The company has also appointed Dr. Sud Agarwal as a special advisor to the CEO and the board of directors with a mandate to advise on strategic aspects of the company's activities and to aid in the advancement of our key programs: QIXLEEF and CAUMZ.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.